Oxidation of methionine - Is it limiting the diagnostic properties of 99mTc-labeled exendin-4, a glucagon-like peptide-1 receptor agonist?

Nuclear Medicine Review

Volumn 19, Issue 2, 2016, Pages 104-110

  Janota, Barbara ^a   Karczmarczyk, Urszula ^a   Laszuk, Ewa ^a   Garnuszek, Piotr ^a   Mikołajczak, Renata ^a  

^a NATIONAL CENTRE FOR NUCLEAR RESEARCH   (Poland)

Author keywords

68GA NODAGA NLE14 exendin 4; 99mTC EDDA HYNIC MET14 exendin 4; 99mTC EDDA HYNIC NLE14 exendin 4; GLP 1; L methionine; Methionine sulfoxide

Indexed keywords

DIGLYCINE DERIVATIVE TC 99M; EXENDIN 4; GALLIUM 68; GLUCAGON LIKE PEPTIDE 1; METHIONINE; NICOTINAMIDE DERIVATIVE; NORLEUCINE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PEPTIDE; TECHNETIUM; VENOM;

ADDITION REACTION; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; DIAGNOSTIC VALUE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIPOPHILICITY; MALE; MOLECULAR STABILITY; NONHUMAN; ORGAN; ORGAN DISTRIBUTION; OXIDATION; PANCREAS; RADIOACTIVITY; RADIOISOTOPE DISTRIBUTION; RAT; STOMACH; AGONISTS; ANIMAL; CHEMICAL PHENOMENA; CHEMISTRY; DRUG STABILITY; OXIDATION REDUCTION REACTION; TISSUE DISTRIBUTION; WISTAR RAT;

ANIMALS; DRUG STABILITY; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; ISOTOPE LABELING; METHIONINE; OXIDATION-REDUCTION; PEPTIDES; RATS; RATS, WISTAR; TECHNETIUM; TISSUE DISTRIBUTION; VENOMS;

EID: 84979915849     PISSN: 15069680     EISSN: None     Source Type: Journal    
DOI: 10.5603/NMR.2016.0021     Document Type: Article

References (32)

1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003; 24: 389-427.
2. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptortumour targeting. Eur J Nucl Med Mol Imaging 2003; 30: 781-793.
3. Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting. J Nucl Med 2007; 48: 736-743.
4. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res 2004; 36: 761-765.
5. Gotthardt M, Fischer M, Naehr I et al. Use of the incretin hormone glucagon- like peptide-1 (GLP-1) for the detection of insulinoma: initial experimental results. Eur J Nucl Med Mol Imaging 2002; 29: 597-606.
6. Gotthardt M, Lalyko G, Behr TM, Behe M. Development of an 111In-labeled GLP-1 analog for the scintigraphic diagnosis of neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2005; 46: 91.
7. Gotthardt M, Lalyko G, van Eerd-Vismale J et al. A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents. Regul Pept 2006; 137: 162-167.
8. Wild D, Behe M, Wicki A et al. [Lys40(Ahx-DTPA-111In)NH2]-exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 2006; 47: 2025-2033.
9. Wicki A, Wild D, Storch D et al. [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 is a highly effcientradiotherapeutic for glucagon-like peptide-1 receptor- Targeted therapy for insulinoma. Clin Cancer Res 2007; 13: 3696-3705.
10. Wild D, Maecke H, Christ E et al. Glucagon-like peptide-1-receptor scans to localize occult insulinomas. N Eng J Med 2008; 359: 766-768.
11. Christ E, Wild D, Forrer F et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endorinol Metab 2009; 94: 4398-4405.
12. Wild D, Wicki A, Mansi R et al. Exendin-4-Based Radiopharmaceuticals for Glucagonlike Peptide-1 Receptor PET/CT and SPECT/CT. J Nucl Med 2010; 51: 1059-1067.
13. Sowa-Staszczak A, Pach D, Mikołajczak R et al. Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. Eur J Nucl Med Mol Imaging 2013; 40: 524-531.
14. Pach D, Sowa-Staszczak A, Jabrocka-Hybel A et al. Glucagon-Like Peptide-1 Receptor Imaging with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-Exendin-4 for the Diagnosis of Recurrence or Dissemination of Medullary Thyroid Cancer: A Preliminary Report. International Journal of Endocrinology Volume 2013, ArticleID384508.
15. Nguyen GK, Lim WH, Nguyen PQ, Tam JP. Novel cyclotides and uncyclotides with highly shortened precursors from Chassalia chartacea and effects of methionine oxidation on bioactivities. J Biol Chem 2012; 287: 17598-17607.
16. Stadtman ER, Van Remmen H, Richardson A, Wehr NB, Levine RL. Methionine oxidation and aging. Biochim Biophys Acta 2005; 1703: 135-140.
17. Breeman W, Fröberg AC, De Blois E et al. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor- Targeting with 3 radiolabeled peptides, Nuclear Medicine and Biology 2008; 35: 839-849.
18. Jodal A, Lankat-Buttgereit B, Brom M, Schibli R, Behe M. A comparison of three 67/68Ga-labelled exendin-4 derivatives for b-cell imaging on the GLP-1 receptor: The influence of the conjugation site of NODAGA as chelator. EJNMMI Research 2014; 4: 31.
19. Kroselj M, Claessens Joosten L, Mansi R et al. Preclinical evaluation of DOTA-coupled minigastrin analogues (Met and corresponding Nle congener). Eur J Nucl Med Mol Imaging 2015; 42: S1-S924.
20. Bauman A, Valverde IE, Fischer CA, Vomstein S, Mindt TL. Development of 68Ga- And 89Zr-labeled Exendin-4 as potential radiotracers for the imaging of insulinomas by PET. J Nucl Med 2015; 56: 1569-1574.
21. Selvaraju RK, Velikyan I, Asplund V et al. Pre-clinical evaluation of [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 for imaging of insulinoma. Nucl Med Biol 2014; 41: 471-476.
22. Mikkola K, Yim CB, Fagerholm V et al. 64Cu- And 68Ga-labelled [Nle14, Lys40(Ahx-NODAGA)NH2-Exendin-4 for pancreatic beta cell imaging in rats. Mol Imaging Biol 2014; 16: 255-263.
23. Pawlak D, Rangger C, Kolenc Peitl P et al. From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial. Eur J Pharm Sci 2016; 85: 1-9.
24. Maurin M, Garnuszek P, Baran P, Pawlak D, Mikołajczak R. The radiometal makes a difference. Synthesis and preliminary characterisation of DOTA-minigastrin analogue complexes with Ga, Lu and Y. Nucl Med Rev 2015; 18: 51-55.
25. Kirkpatrick A, Heo J, Abrol R, Goddard WA. Predicted structure of agonist-bound glucagon-like peptide 1 receptor, classB g protein-coupled receptor. Proc Natl Acad Sci USA 2012; 109: 19988-19993.
26. Yim CB, Mikkola K, Fagerholm V et al. Synthesis and preclinical characterization of [64Cu]NODAGA-MAL-exendin-4 with a Ne-maleoyl-l-lysyl-glicine linkage. Nucl Med Biol 2013; 40: 1006-1012.
27. Berry DJ, Ma Y, Ballinger JR et al. Efficient bifunctional gallium-68 chelators for positron emission tomography: Tris(hydroxypyridinone) ligands. Chem Commun 2011; 47: 7068-7070.
28. Gotthardt M, van Eerd-Vismale J, Oyen WJG et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med 2007; 48: 596-601.
29. Bernard BF, Krenning EP, Breeman WAP et al. D-Lysine reduction of indium- 111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997; 38: 1929-1933.
30. Melis M, Krenning EP, Bernard BF, Barone R, Visser TJ, de Jong M. Localisation and mechanism of renal retention of radiolabeled somatostatin analogues. Eur J Nucl Med Mol Imaging 2005; 32: 1136-1143.
31. Trejtnar F, Laznicek M, Laznickova A, Mather SJ. Pharmacokinetics and renal handling of 99mTc-labeled peptides. J Nucl Med 2000; 41: 177-182.
32. Vegt E, Eek A, Oyen WJG, de Jong M, Gotthardt M, Boerman OC. Albumin-derived peptides efficiently reduce renal uptake of radiolabeled peptides. Eur J Nucl Med Mol Imaging 2010; 37: 226-234.